
Novartis' Scemblix Gets Positive CHMP Opinion For Treatment Of Chronic Myeloid Leukemia
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization for Scemblix or asciminib for the treatment of adult patients with Philadelphia …